Evidence map›Paper›PMID 30562358›Full record

ArticlePloS one2018

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort.

Oumar Billa, Mathieu Chalouni, Dominique Salmon, Isabelle Poizot-Martin, Camille Gilbert, Christine Katlama, Didier Neau, Julie Chas, Philippe Morlat, Karine Lacombe and 22 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 19 institutions in 1 country.

Oumar BillaUniv Bordeaux, ISPED, Inserm Bordeaux Population Health, team MORPH3EUS, UMR 1219, CIC-EC 1401, Bordeaux, France.
Mathieu ChalouniUniv Bordeaux, ISPED, Inserm Bordeaux Population Health, team MORPH3EUS, UMR 1219, CIC-EC 1401, Bordeaux, France.
Dominique SalmonUniversité Paris Descartes, Paris, France.
Isabelle Poizot-MartinAix Marseille Université, APHM Hôpital Sainte-Marguerite, Service d'Immuno-hématologie clinique, Marseille, France.
Camille GilbertUniv Bordeaux, ISPED, Inserm Bordeaux Population Health, team MORPH3EUS, UMR 1219, CIC-EC 1401, Bordeaux, France.
Christine KatlamaAssistance Publique des Hôpitaux de Paris, Hôpital Pitié-Salpétrière, Service Maladies infectieuses et tropicales, Paris, France.
Didier NeauCentre Hospitalier Universitaire de Bordeaux, Service Maladies infectieuses et tropicales Bordeaux, Hôpital Pellegrin, Bordeaux, France.
Julie ChasAssistance Publique des Hôpitaux de Paris, Hôpital Tenon, Service Maladies infectieuses et tropicales, Paris, France.
Philippe MorlatUniv Bordeaux, ISPED, Inserm Bordeaux Population Health, team MORPH3EUS, UMR 1219, CIC-EC 1401, Bordeaux, France.
Karine LacombeAssistance Publique des Hôpitaux de Paris, Hôpital Saint-Antoine, Service Maladies infectieuses et tropicales, Paris, France.
Alissa NaqviCentre Hospitalier Universitaire de Nice, Service d'Infectiologie, Hôpital Archet 1, Nice, France.
Karl BarangeCentre Hospitalier Universitaire de Toulouse, Service Gastro-entérologie et hépatologie, Hôpital Purpan, Toulouse, France.
Anne GervaisAssistance Publique des Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Service des maladies infectieuses et tropicales, Paris, France.
Olivier BouchaudAssistance Publique des Hôpitaux de Paris, Hôpital Avicenne, Service Maladies infectieuses et tropicales, Bobigny, France.
Eric RosenthalCentre Hospitalier Universitaire de Nice, Service de Médecine Interne et Cancérologie, Hôpital l'Archet, Nice, France.
Caroline Lascoux-CombeAssistance Publique des Hôpitaux de Paris, Hôpital Saint-Louis, Service des Maladies infectieuses et tropicales, Paris, France.
Daniel GaripuyCentre Hospitalier Universitaire de Toulouse, Hôpital Purpan, Services des Maladies infectieuses et tropicales, Toulouse, France.
Laurent AlricCentre Hospitalier Universitaire de Toulouse, Hôpital Purpan, Services de Médecine interne-Pole Digestif, Toulouse, France.
Stéphanie DominguezAssistance Publique des Hôpitaux de Paris, Hôpital Henri Mondor, Service Immunologie clinique et maladies infectieuses, Immunologie clinique, Créteil, France.
Daniel VittecoqAssistance Publique des Hôpitaux de Paris, Hôpital Bicêtre, Hôpitaux universitaires Paris Sud, Service Maladies infectieuses et tropicales, Le Kremlin-Bicêtre, France.
Cécile GoujardAssistance Publique des Hôpitaux de Paris, Hôpital Bicêtre, Hôpitaux universitaires Paris Sud, Service Médecine interne et Immunologie clinique, Le Kremlin-Bicêtre, France.
Claudine DuvivierAssistance Publique des Hôpitaux de Paris, Service de Maladies Infectieuses et Tropicales, Hôpital Necker-Enfants malades, Centre d'Infectiologie Necker-Pasteur, IHU Imagine, Paris, France.ORCID 0000-0001-5696-4173
Hugues AumaitreCentre Hospitalier de Perpignan, Service Maladies infectieuses et tropicales, Perpignan, France.
Patrick MiailhesCentre Hospitalier Universitaire de Lyon, Service des Maladies Infectieuses et Tropicales, Hôpital de la Croix Rousse, Lyon, France.
David ZucmanHôpital Foch, unité VIH, Suresnes, France.
Anne SimonAssistance Publique des Hôpitaux de Paris, Hôpital Pitié-Salpétrière, Département de Médecine Interne et Immunologie Clinique, Paris, France.
Estibaliz LazaroCentre Hospitalier Universitaire de Bordeaux, hôpital Haut-Lévèque, Service de Médecine interne et Maladies Infectieuses, Pessac, France.
François RaffiCHU de Nantes, Department of Infectious Diseases, Nantes, France.
Laure EsterleUniv Bordeaux, ISPED, Inserm Bordeaux Population Health, team MORPH3EUS, UMR 1219, CIC-EC 1401, Bordeaux, France.ORCID 0000-0002-1017-1327
Linda WittkopUniv Bordeaux, ISPED, Inserm Bordeaux Population Health, team MORPH3EUS, UMR 1219, CIC-EC 1401, Bordeaux, France.
Firouzé Bani-SadrCentre Hospitalier Universitaire de Reims, Unité des Maladies Infectieuses et Tropicales, Hôpital Robert Debré, Reims, France.
ANRS CO13 HEPAVIH Study Group
Université de Bordeaux · FRSorbonne Université · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire de Toulouse · FRInserm · FRCentre Hospitalier de Perpignan · FRCentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Nice · FRCentre Hospitalier Universitaire de Reims · FRDélégation Paris 5 · FRHôpital de la Croix-Rousse · FRHôpital Foch · FRHôpital Necker-Enfants Malades · FRHôpital Saint-Louis · FRUniversité Claude Bernard Lyon 1 · FRUniversité Côte d'Azur · FRUniversité Sorbonne Nouvelle · FRUniversité Sorbonne Paris Nord · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Compared to the general population, HIV-infected patients are at higher risk of developing non-AIDS-defining cancers. Chronic HCV infection has also been associated with a higher risk than that of the general population of developing cancers other than hepatocarcinoma. Evaluation of the impact of HCV-related factors on non-AIDS-defining and non HCV-liver (NANL) related cancers among HIV/HCV co-infected patients are scarce. The aim of this study was to identify the impact of HIV/HCV clinical characteristics on NANL related cancers in a large cohort of HIV/HCV-coinfected patients followed from 2005 to 2017. Cox proportional hazards models with delayed entry were used to estimate factors associated with NANL related cancer. Among 1391 patients followed for a median of 5 years, 60 patients developed NANL related cancers, yielding an incidence rate of 8.9 per 1000 person-years (95% CI, [6.6-11.1]). By final multivariable analysis, after adjustment for sex, tobacco or alcohol consumption, baseline CD4 cell count and HCV sustained viral response (SVR), age and a longer duration since HIV diagnosis were independently associated with a higher risk of NANL related cancer (aHR for each additional year 1.10, 95% CI 1.06-1.14, p<0.0001 and 1.06, 95% CI 1.01-1.11, p = 0.02, respectively). Duration of HCV infection, cirrhosis, HCV viral load, genotype and SVR were not associated with the occurrence of NANL related cancer. Among HIV/HCV-coinfected patients, age and the duration of HIV infection were the only characteristics found to be associated with the occurrence of NANL related cancer. In contrast, no association was observed with any HCV-related variables.

Indexed as

AdultCoinfectionFemaleHepatitis CHIV InfectionsHumansLiver CirrhosisLiver NeoplasmsMaleMiddle AgedProspective StudiesRisk Factors

Identifiers

PMID30562358
PMCPMC6298669
OpenAlexW2905360623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.